Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).

• DOI: 10.1200/jco.2018.36.15_suppl.e15155
• Publication Date: 2018-09-05T14:27:01Z
• Authors: Morten Mau Soerensen; Willeke Ros; Maria E. Rodrigue...; Debbie Robbrecht; Kristoffer Staal ...; Juan Martin-Liberal; Ulrik Niels Lassen; Ignacio Melero Be...; Martijn P. Lolkema; Josep Tabernero; Christophe Boetsch; Hanna Piper-Lepoutre; Inja Waldhauer; Jehad Charo; Stefan Evers; Volker Teichgräber; Jan H. M. Schellens
• Keywords: 0303 health sciences; 03 medical and health sciences; 3. Good health

e15155Background: High-dose (HD) IL-2 is approved for patients with melanoma and renal cell carcinoma but is associated with significant toxicity, given only in an inpatient setting. RO6874281 is a...